Antihypertensive Treatment in Obese Patients: A gap Between Guidelines and Real-World Practise
Table of Contents
obesity is a significant risk factor for hypertension, dramatically increasing the risk of cardiovascular disease. Despite the growing prevalence of obesity and specific guidelines for managing arterial hypertension, dedicated recommendations for obese hypertensive patients remain limited. A recent retrospective study investigated antihypertensive treatment patterns in obese patients over the past eight years, revealing a discrepancy between clinical guidelines and actual prescribing habits. This analysis underscores the need for improved adherence to evidence-based recommendations to optimize therapeutic outcomes and medication adherence in this high-risk population.
The Link Between Obesity and Hypertension
Obesity and hypertension frequently coexist, creating a synergistic effect that significantly elevates cardiovascular risk. Several factors contribute to this relationship:
* Increased Blood Volume: Obesity often leads to increased blood volume, placing greater strain on the cardiovascular system.
* Sympathetic Nervous System Activation: Excess adipose tissue can activate the sympathetic nervous system, leading to vasoconstriction and increased blood pressure. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.13199
* Renin-Angiotensin-Aldosterone System (RAAS) Activation: Obesity can disrupt the RAAS, contributing to sodium retention and increased blood pressure.
* Inflammation: Obesity is associated with chronic low-grade inflammation, which can damage blood vessels and contribute to hypertension.
Study Findings: Treatment Patterns and guideline Adherence
The retrospective study, focusing on obese patients undergoing preoperative assessment for bariatric surgery, analyzed medical records of 233 individuals. The cohort was divided into those diagnosed before 2020 and those diagnosed in 2020 or later. Key findings include:
* Increased Polypharmacy: A significant increase was observed in the use of three or more antihypertensive drugs after 2020. This suggests increasing disease severity or challenges in controlling blood pressure with fewer medications.
* Shifting Prescribing Trends: Prescriptions for beta-blockers and angiotensin receptor blockers (ARBs) rose after 2020.
* Low Single-Pill Combination (SPC) Use: Despite recommendations from both european and Polish guidelines since 2018 to utilize SPCs at all stages of treatment, their use remained surprisingly low. Only 35.6% of patients received two-drug SPCs, and a mere 11.2% received three-drug SPCs. Moreover, there was no significant increase in SPC usage over time.
* Emergence of SGLT2 Inhibitors: Sodium-glucose cotransporter-2 (SGLT2) inhibitors were introduced into therapy for some patients after 2020, reflecting their growing role in cardiovascular and metabolic management. https://www.acc.org/latest-in-cardiology/clinical-tool-summaries/2023/07/27/16/33/sglt2-inhibitors-for-heart-failure-and-cv-risk-reduction
The Importance of Single-Pill Combinations
SPCs offer several advantages over prescribing multiple individual pills:
* Improved Adherence: Simplifying the medication regimen with a single pill increases the likelihood that patients will take their medications as prescribed. Poor adherence is a major barrier to effective hypertension control.
* Reduced Pill Burden: A lower pill burden can improve patient convenience and reduce the risk of medication errors.
* cost-Effectiveness: SPCs can sometimes be more cost-effective than prescribing individual medications.
Why the Discrepancy?
The study highlights a concerning gap between guideline recommendations and real-world clinical practice. several factors may contribute to this discrepancy:
* Physician Awareness: Lack of awareness or familiarity with the latest guideline recommendations.
* Prescribing Habits: Established prescribing habits and reluctance to change practice patterns.
* Patient Preferences: Patient preferences or concerns about potential side effects of specific medications.
* Reimbursement issues: Potential challenges with insurance coverage or reimbursement for SPCs.
Key Takeaways
* Obesity significantly increases the risk of hypertension and cardiovascular disease.
* Current guidelines recommend single-pill combinations (SPCs) for managing hypertension at all stages.
* A recent study revealed low SPC utilization among obese hypertensive patients, despite guideline recommendations.